NeOnc Technologies Appoints Renowned Neuro-Oncologist Dr. Henry S. Friedman to Scientific Advisory Board

Core Insights - NeOnc Technologies Holdings, Inc. has appointed Dr. Henry S. Friedman to its scientific advisory board, enhancing its expertise in neuro-oncology [1][2][4] - Dr. Friedman is a prominent figure in the field, with over 500 peer-reviewed publications and extensive experience in developing therapies for CNS cancers [4] - The company is preparing to publish data from its clinical programs NEO100 and NEO212, which are in Phase II trials and have received FDA Fast-Track and IND status [3][5] Company Overview - NeOnc Technologies is a clinical-stage biopharmaceutical company focused on developing therapies for central nervous system cancers, particularly addressing challenges related to the blood-brain barrier [5] - The company's NEO™ drug development platform has produced a portfolio of novel drug candidates with patent protections extending to 2038 [5] - NEO100 and NEO212 are proprietary chemotherapy agents that have shown positive effects in laboratory tests and clinical trials for malignant gliomas [5] Leadership and Strategy - The appointment of Dr. Friedman is expected to strengthen the company's pipeline and enhance stakeholder confidence as it advances its clinical programs [2][3] - The company aims to change the future for patients with glioblastoma and other brain cancers through innovative therapies and collaborative research efforts [3][4]